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Background: Nevirapine, a component of antiretroviral therapy
(ART) in resource-limited settings is known for auto-induction of
metabolism, and thus is prescribed at half therapeutic dose until
day14 (‘lead-in period’), and then escalated to full dose. However,
young children have higher clearance rates, suggesting that dos-
ing strategy based on adult studies may not be appropriate in
children. We aimed to determine plasma nevirapine concentra-
tions achieved during the ﬁrst month among children initiated on
nevirapine-containing ART
Methods &Materials: ART-naïve HIV-infected children, initiat-
ing ARTwere included in this prospective study. Plasma nevirapine
trough levels were analyzed in duplicate (with additional 10%
repeats for quality control) by high performance liquid chromatog-
raphy (HPLC) (lowest detection limit 0.062 g/ml) at days 7, 14
(lead-in period) and 28 (full dose) after ART initiation. Baseline
transmitted drug resistance genotyping, serial CD4 count and viral
load was done.
Results: Among 28 children aged 2-12 years initiated on
nevirapine-based ART between 2013-2014, six were excluded due
to drug toxicity, and two were transferred out within ﬁrst month.
Among 20 children included in the study, 19 reported >95% adher-
ence at all study visits. Transmitted drug resistance was seen in
5(10%) children (V90I, K103N, K101E, E138G, Y188L,M41L, L210W,
T215Y). Median trough nevirapine concentration was 4.83g/ml
(IQR 3.48-6.06) at day 7 of ART initiation, 3.35g/ml (IQR 2.06-
7.91) at day 14 (lead-in period), and 7.97g/ml (IQR 5.55-10.66)
on day 28 (p= 0.018). During the lead-in period 40% (8/20; 15%
at day 7, 35% at day 14) of children failed to achieve therapeutic
levels of >3 g/ml, while after dose escalation, only 5% (1/20) had
low therapeutic levels. Low trough nevirapine levels was not sig-
niﬁcantly associated with age, viral load, CD4 count or transmitted
drug resistance.
Conclusion: Our results showed signiﬁcantly lower therapeu-
tic concentrations of nevirapine during the lead-in period in young
children initiating nevirapine-based ART in India. Given nevirap-
ine’s low genetic barrier, sub-therapeutic levels during the early
high viremic period can lead to later drug resistance development
and treatment failure. Long-term drug resistance studies among
viral quasispecies can determine the true effect of early subthera-
peutic concentrations
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Knowledge and practice of the prevention of
mother-to-child transmission of HIV guidelines
among doctors and nurses at Tswane District,
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Background: Since the beginning of the HIV/AIDS epidemic,
almost 60 million people have been infected and 25 million people
have already died fromHIV related causes, (WHO, 2010). Sub Saha-
ran Africa is the region most affected with 67% of all people living
with HIV worldwide and 91% of all new infections among children.
In South Africa, the mother-to-child HIV transmission (MTCT) rate
is under 4% at 4 to 8 weeks after birth since the implementation
of the most recent national PMTCT programme. The PMTCT pro-
gramme in South Africa has gained rapid momentum in training
and practice.
Methods & Materials: This study was conducted in Gauteng
province of South Africa. We sought to investigate the level of
knowledge and whether the doctors and nurses working at Odi
were practicing the current PMTCT program. A descriptive cross
sectional survey using self-administered questionnaires was used.
The study population consisted of 31 doctors and 180 nurses.
Results: There were 102 participants. There were 12 (12%) doc-
tors and 90 (88%) professional nurses. There 9 (9%) males and
93 (91%) females. Thirty four participants (33%) underwent fur-
ther training beyond their undergraduate qualiﬁcation. The mean
knowledge percentage per participant was 60.8% and 77% for the
mean practice percentage per participant. In the knowledge ques-
tions, the question on the ﬁrst step (HIV counseling and testing)
scored an average 93.1% (highest) by participants and the doses of
drugsused in thePMTCTguidelines scored17.7% (lowest) bypartic-
ipants. In the practice questions, the score for each question ranged
from 71% to 82%.
Conclusion: Nurses and doctors working at Odi Hospital know
that HIV counseling and testing is important and must be done on
all mothers; however they were unsure of the dosages of the drugs
used for PMTCT. More than two thirds of the doctors and nurses
reported to be practicing the PMTCT guidelines, however as their
knowledge was inadequate, their enthusiasm is lost by actually
not knowing the correct drugs and dosages for the PMTCT which
impacts on the correct PMTCT practice.
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